表纸
市场调查报告书

人体生长荷尔蒙的全球市场:2018~2022年

Global Human Growth Hormone Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品编码 320559
出版日期 内容资讯 英文 110 Pages
订单完成后即时交付
价格
Back to Top
人体生长荷尔蒙的全球市场:2018~2022年 Global Human Growth Hormone Market 2018-2022
出版日期: 2018年12月14日内容资讯: 英文 110 Pages
简介

由于生长激素缺乏导致生长激素紊乱的发病率和罹患率增加,预计将在预测期内推动人类生长激素市场的发展。全球人体生长荷尔蒙市场到2022年前预测将以年复合成长率4%扩大。

本报告提供全球人体生长荷尔蒙市场相关调查,汇整市场趋势与各市场区隔趋势,各地区预测,加入此市场的供应商简介等相关资讯。

第1章 摘要整理

第2章 调查范围

第3章 调查方法

第4章 市场情况

  • 市场生态系统
  • 市场特性
  • 市场区隔分析

第5章 开发平台分析

第6章 市场规模

  • 市场定义
  • 市场规模(2017年)
  • 市场规模与预测(2017~2022年)

第7章 波特的五力分析

  • 买主谈判力
  • 供应商谈判力
  • 新加入厂商者的威胁
  • 替代品的威胁
  • 对手的威胁
  • 市场情形

第8章 按药物市场区隔

第9章 各用途市场市场区隔

  • 市场区隔
  • 比较
  • 生长激素缺乏
  • ISS
  • 透纳氏症
  • PWS
  • 其他

第10章 竞争环境

第11章 各地区趋势

  • 市场区隔
  • 比较
  • 南北美洲
  • 欧洲·中东·非洲
  • 亚太地区
  • 市场机会

第12章 决策架构

第13章 促进要素与课题

第14章 市场趋势

第15章 供应商环境

第16章 供应商分析

  • 网罗的供应商
  • 供应商分类
  • 供应商的市场定位
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Pfizer

第17章 附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: IRTNTR23746

About this market

Increasing incidence and prevalence of growth hormone disorders due to the growth hormone deficiency is expected to drive the human growth hormone market over the forecast period. Moreover, various indications fall under the growth hormone disorders such as turner syndrome, growth hormone deficiency, acromegaly, Noonan syndrome, gigantism, and many more. Technavio's analysts have predicted that the human growth hormone market will register a CAGR of almost 4% by 2022.

Market Overview

Strong pipeline of human growth hormone

Many leading companies such as Novo Nordisk, Merck, and Pfizer have a strong pipeline in their portfolio for treating various growth hormone disorders. All these factors are expected to drive the global human growth hormone market during the forecast period.

Poor patient adherence

The poor patient adherence for human growth hormone due to uneasiness with growth hormone administration will impact the treatment adherence and results.

For the detailed list of factors that will drive and challenge the growth of the human growth hormone market during the 2018-2022, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Novo Nordisk and Pfizer the competitive environment is quite intense. Factors such as the strong pipeline of human growth hormone and the increasing incidence and prevalence of growth hormone disorders, will provide considerable growth opportunities to human growth hormone manufactures. Eli Lilly, F. Hoffmann-La Roche, Novo Nordisk, and Pfizer are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Human growth hormone pipeline analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY DRUG TYPE

  • Segmentation by drug type

PART 09: MARKET SEGMENTATION BY APPLICATION

  • Segmentation by application
  • Comparison by application
  • Growth hormone deficiency - Market size and forecast 2017-2022
  • ISS - Market size and forecast 2017-2022
  • Turner syndrome - Market size and forecast 2017-2022
  • PWS - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by application

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

  • Increasing incidence of growth disorders
  • No impact of biosimilar entry into market
  • Advanced technologies

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Pfizer

PART 17: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global human growth hormone market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline drugs under Phase III stage of development 2017-2018
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Application - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by application
  • Exhibit 21: Growth hormone deficiency - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 22: Growth hormone deficiency - Year-over-year growth 2018-2022 (%)
  • Exhibit 23: ISS- Market size and forecast 2017-2022 ($ mn)
  • Exhibit 24: ISS - Year-over-year growth 2018-2022 (%)
  • Exhibit 25: Turner syndrome - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 26: Turner syndrome - Year-over-year growth 2018-2022 (%)
  • Exhibit 27: PWS - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 28: PWS - Year-over-year growth 2018-2022 (%)
  • Exhibit 29: Others - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 30: Others - Year-over-year growth 2018-2022 (%)
  • Exhibit 31: Market opportunity by application
  • Exhibit 32: Customer landscape
  • Exhibit 33: Global - Market share by geography 2017-2022 (%)
  • Exhibit 34: Regional comparison
  • Exhibit 35: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 36: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 37: Top 3 countries in Americas
  • Exhibit 38: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 39: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 40: Top 3 countries in EMEA
  • Exhibit 41: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 42: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 43: Top 3 countries in APAC
  • Exhibit 44: Market opportunity
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: Eli Lilly - Overview
  • Exhibit 51: Eli Lilly - Business segments
  • Exhibit 52: Eli Lilly - Organizational developments
  • Exhibit 53: Eli Lilly - Geographic focus
  • Exhibit 54: Eli Lilly - Segment focus
  • Exhibit 55: Eli Lilly - Key offerings
  • Exhibit 56: Eli Lilly - Key customers
  • Exhibit 57: F. Hoffmann-La Roche - Overview
  • Exhibit 58: F. Hoffmann-La Roche - Business segments
  • Exhibit 59: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 60: F. Hoffmann-La Roche - Geographic focus
  • Exhibit 61: F. Hoffmann-La Roche - Segment focus
  • Exhibit 62: F. Hoffmann-La Roche - Key offerings
  • Exhibit 63: F. Hoffmann-La Roche - Key customers
  • Exhibit 64: Novo Nordisk - Overview
  • Exhibit 65: Novo Nordisk- Business segments
  • Exhibit 66: Novo Nordisk - Organizational developments
  • Exhibit 67: Novo Nordisk - Geographic focus
  • Exhibit 68: Novo Nordisk - Segment focus
  • Exhibit 69: Novo Nordisk- Key offerings
  • Exhibit 70: Pfizer - Overview
  • Exhibit 71: Pfizer - Business segments
  • Exhibit 72: Pfizer - Organizational developments
  • Exhibit 73: Pfizer - Geographic focus
  • Exhibit 74: Pfizer - Segment focus
  • Exhibit 75: Pfizer - Key offerings
  • Exhibit 76: Pfizer - Key customers
Back to Top